Drug General Information
Drug ID
D05KXP
Former ID
DNC007012
Drug Name
8-n-undecylnaringenin
Drug Type
Small molecular drug
Indication Discovery agent Investigative [528557]
Structure
Download
2D MOL

3D MOL

Formula
C26H34O5
Canonical SMILES
CCCCCCCCCCCC1=C(C=C(C2=C1OC(CC2=O)C3=CC=C(C=C3)O)O)O
InChI
1S/C26H34O5/c1-2-3-4-5-6-7-8-9-10-11-20-21(28)16-22(29)25-23(30)17-24(31-26(20)25)18-12-14-19(27)15-13-18/h12-16,24,27-29H,2-11,17H2,1H3/t24-/m0/s1
InChIKey
MQGTUCCMXKRAMD-DEOSSOPVSA-N
PubChem Compound ID
Target and Pathway
Target(s) Estrogen receptor Target Info Inhibitor [528557]
Estrogen receptor beta Target Info Inhibitor [528557]
KEGG Pathway Estrogen signaling pathway
Prolactin signaling pathway
Thyroid hormone signaling pathway
Endocrine and other factor-regulated calcium reabsorption
Proteoglycans in cancerhsa04915:Estrogen signaling pathway
NetPath Pathway FSH Signaling Pathway
EGFR1 Signaling Pathway
RANKL Signaling Pathway
Pathway Interaction Database Regulation of nuclear SMAD2/3 signaling
Signaling events mediated by HDAC Class II
Plasma membrane estrogen receptor signaling
LKB1 signaling events
Regulation of Telomerase
ATF-2 transcription factor network
AP-1 transcription factor network
FOXM1 transcription factor network
Validated nuclear estrogen receptor alpha network
Signaling mediated by p38-alpha and p38-beta
FOXA1 transcription factor networker_nongenomic_pathway:Plasma membrane estrogen receptor signaling
Validated nuclear estrogen receptor beta network
Reactome Nuclear signaling by ERBB4
Nuclear Receptor transcription pathwayR-HSA-383280:Nuclear Receptor transcription pathway
WikiPathways Estrogen signaling pathway
Nuclear Receptors Meta-Pathway
Estrogen Receptor Pathway
Signaling by ERBB4
JAK/STAT
Integrated Pancreatic Cancer Pathway
Leptin signaling pathway
miR-targeted genes in muscle cell - TarBase
Integrated Breast Cancer Pathway
Nuclear ReceptorsWP706:SIDS Susceptibility Pathways
Ovarian Infertility Genes
Nuclear Receptors
References
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.
Ref 528557J Med Chem. 2006 Dec 14;49(25):7357-65.Subtle side-chain modifications of the hop phytoestrogen 8-prenylnaringenin result in distinct agonist/antagonist activity profiles for estrogen receptors alphaand beta.

If you find any error in data or bug in web service, please kindly report it to Dr. Wang and Dr. Li.